1211541-93-3

Usage

Uses

Used in Pharmaceutical Industry:
5-Fluoro-2-Methoxy-pyridin-3-ylaMine is used as a building block for the synthesis of new drugs due to its potential pharmacological properties. Its unique structure allows for the creation of diverse compounds with potential therapeutic applications.
Used in Agrochemical Industry:
5-Fluoro-2-Methoxy-pyridin-3-ylaMine is used as a building block for the development of new agrochemical products, such as pesticides, due to its potential pesticidal properties. Its unique structure and functional groups contribute to the creation of compounds with effective pest control capabilities.
The synthesis and properties of 5-Fluoro-2-Methoxy-pyridin-3-ylaMine are of significant interest to researchers and pharmaceutical companies, as they seek to develop new chemical entities with improved efficacy and safety profiles.

Upstream product

• 84476-99-3 2,5-difluoropyridine 
• 1211534-27-8 5-fluoro-2-methoxy-3-nitropyridine 
• 136888-20-5 5-fluoro-2-hydroxy-3-nitropyridine 
• 51173-05-8 5-fluoropyridin-2-ol 

Relevant academic research and scientific papers

PYRIDINYL AND PYRAZINYL-(AZA)INDOLSULFONAMIDES

The present invention relates to pyridinyl and pyrazinyl-(aza)indolsulfonamides having GPR17 modulator activity. The compounds have utility in the treatment of a variety of GPR17-associated disorders.

Identification of 2-Imidazopyridine and 2-Aminopyridone Purinones as Potent Pan-Janus Kinase (JAK) Inhibitors for the Inhaled Treatment of Respiratory Diseases

Janus kinases (JAKs) have a key role in regulating the expression and function of relevant inflammatory cytokines involved in asthma and chronic obstructive pulmonary disease. Herein are described the design, synthesis, and pharmacological evaluation of a series of novel purinone JAK inhibitors with profiles suitable for inhaled administration. Replacement of the imidazopyridine hinge binding motif present in the initial compounds of this series with a pyridone ring resulted in the mitigation of cell cytotoxicity. Further systematic structure-activity relationship (SAR) efforts driven by structural biology studies led to the discovery of pyridone 34, a potent pan-JAK inhibitor with good selectivity, long lung retention time, low oral bioavailability, and proven efficacy in the lipopolysaccharide-induced rat model of airway inflammation by the inhaled route.

MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER

Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.

Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases

New pyridin-2(1h)-one derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

PYRIDIN-2 (1H) -ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES

Compoundshaving the chemical structure of formula (I) are disclosed; as well as process for theirpreparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).